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Abstract 
Purpose: To elucidate the solid-state conformation as well as the imine double bond configuration of a 
potential anti-Candida agent ({[(1E)-3-(1H-imidazol-1-yl)-1-phenylpropylidene]amino}oxy)(3,4,5-
trimethoxyphenyl)methanone. 
Methods: Acetophenone was used as a starting material to prepare the target oximino ester in a four-
step reaction sequence. Nuclear magnetic resonance (1H-NMR and 13C-NMR) and mass spectrometry 
were used to confirm the chemical structure of the synthesized compounds. Thereafter, x-ray 
crystallography was performed on single crystals of the target compound.  The solid-state conformation 
of the target molecule and the (E)-configuration of its imine double bond were determined via the 
investigation of its single crystal x-ray molecular structure.  
Results: The titled compound crystallized in the triclinic space group P-1 with a = 11.0719 (7) Å, b = 
14.6602 (9) Å, c = 14.8530 (9) Å, α = 67.205 (4)°, β = 80.388 (5)º, γ = 70.100 (5)°, V = 2088.2 (2) Å3, 
and Z = 4. Individual molecules were packed in the crystal by three weak non-classical intermolecular 
hydrogen interactions, including C9A—H9AA•••O3A, C9B—H9BA•••O3B, C18B—H18C•••O2A and 
C20B—H20B•••O4B.  
Conclusion: The results of the single crystal x-ray molecular structure of the titled anti-Candida agent 
unequivocally confirmed its (E)-configuration.  
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A substantial increase in fungal infections has 
been observed over the past few decades. 
Invasive and nosocomial fungal infections are 
primarily caused by Candida and Aspergillus 
species, where Candida albicans is responsible 
for the majority of invasive and superficial 
Candida infections.  
 
The azole antifungal agents constitute a major 
antifungal class and contain an azole 
pharmacophoric moiety. In spite of the fact that 
there is a growing list of new antifungal agents, 
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the treatment of fungal infections remains 
unsatisfactory in many cases. Furthermore, the 
use of many antifungal drugs is often 
complicated by clinical obstacles, including a 
suboptimal spectrum of activity, hazardous drug-
drug interactions, toxicity, and limited 
bioavailability [1-6]. Consequently, the search for 
novel antifungal agents is urgently needed for 
clinical therapy. 
 
The molecular structure of the anti-Candida 
oximino ester, namely ({[(1E)-3-(1H-imidazol-1-
yl)-1-phenylpropylidene]amino}oxy)(3,4,5-trimet- 
hoxyphenyl)methanone (4) has not been 
previously investigated. Herein, we report the 
molecular structure as well as the configuration 
of the imine moiety of the oximino ester 4 using 
x-ray crystallography as an unambiguous 






Melting points were determined on a Gallenkamp 
melting point apparatus and are uncorrected. 
NMR spectra were carried out on a Bruker NMR 
spectrometer operating at 500 MHz for 1H and 
125.76 MHz for 13C at the Research Center, 
College of Pharmacy, King Saud University, 
Saudi Arabia. Tetramethylsilane (TMS) was used 
as internal standard and chemical shift values 
were recorded in ppm on δ scale. 1H-NMR data 
were represented as follows: chemical shifts, 
multiplicity (s. singlet, d. doublet, t. triplet, m. 
multiplet) and number of protons. The 13C-NMR 
data were represented as chemical shifts and 
type of carbon. Mass spectra were measured on 
Agilent Triple Quadrupole 6410 QQQ LC/MS with 
an electrospray ionization (ESI) source. X-ray 
diffraction measurements of the target oximino 
ester 4 were performed using Bruker SMART 
APEXII CCD diffractometer. Crystallographic 
data of the title anti-Candida agent 4 has been 
deposited with the Cambridge Crystallographic 
Data Center (supplementary publication numbers 
CCDC-1048685). Copies of the data can be 
obtained free of charge from the Director, CCDC, 





Preparation of 3-(1H-imidazol-1-yl)-1-phenyl- 
propan-1-one (2)  
 
A catalytic amount of concentrated hydrochloric 
acid (0.1 mL) was added to a mixture of 
acetophenone (2.4 g, 20 mmol), dimethylamine 
hydrochloride (2.2 g, 27 mmol) and paraform-
aldehyde (0.81 g, 9 mmol). The reaction mixture 
was refluxed in absolute ethanol (5 mL) for two 
hours. Acetone (20 mL) was added to the cooled 
reaction mixture in order to precipitate the 
Mannich base hydrochloride 1. A solution 
containing compound 1 (3.7 g, 17.4 mmol) and 
imidazole (2.4 g, 34.8 mmol) in water (10 mL) 
was refluxed for five hours. Cooling the reaction 
mixture led to precipitation of the ketone 2 which 
was filtered off to give 2.7 g (77%) of 2 mp 368-
370 K [7]. Ketone 2 was used in the next step 
without any further purification, and its chemical 
structure was confirmed via 1H and 13C NMR. 
 
Preparation of (1E)-N-hydroxy-3-(1H-imidazol-
1-yl)-1-phenylpropan-1-imine (3)  
 
Hydroxylamine hydrochloride (1.39 g, 20 mmol) 
was added to a solution containing ketone 2 
(2.00 g, 10 mmol) and KOH (1.12 g, 20 mmol) in 
ethanol (10 mL). The reaction was stirred under 
reflux for 18 h, cooled to ambient temperature, 
and filtered. After concentrating the filtrate under 
reduced pressure, the residue was poured onto 
ice-cold water (15 mL). The precipitated solid 
was filtered, dried and re-crystallized from 
ethanol to yield 1.51 g (70 %) of compound 3 as 
colorless crystals with mp 428-430 K [8]. The 
assigned chemical structure of oxime 3 was 





oxyphenyl)methanone (4)  
 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI.HCl, 1.40 g, 7.3 mmol) was added to a 
stirred solution containing 3,4,5-
trimethoxybenzoic acid (1.49 g, 7 mmol) and 4-
dimethylaminopyridine (DMAP, 400 mg) in 
dichloromethane (75 mL). Thereafter, oxime 3 
(1.49 g, 6.9 mmol) was added and the reaction 
mixture was stirred at ambient temperature for 18 
h. The reaction mixture was successively 
washed with water (2 x 20 mL), a 10 % NaHCO3 
solution (2 x 15 mL), and water (2 x 15 mL). The 
organic phase was separated, dried (Na2SO4), 
and evaporated under vacuum. The residue was 
re-crystallized (isopropanol) to yield 1.50 g (53 
%) of the target oximino ester 4 as colorless 
crystals with mp 408-410 K [8]. The assigned 
chemical structure of compound 4 was confirmed 
via 1H and 13C NMR and mass spectral data. 
 
Crystal structure determination 
 
The slow evaporation of the isopropanol solution 
containing pure oximino ester 4 afforded its 
colorless block single crystals. A single crystal 
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with dimensions of 0.32 × 0.23 × 0.05 mm was 
selected for x-ray diffraction analysis. Data were 
collected on a Bruker APEX-II CCD area 
diffractometer equipped with graphite 
monochromatic CuKa radiation (λ = 1.54178 Å) 






Oximino ester 4 was obtained as shown in 
Scheme 1. Briefly, acetophenone was subjected 
to a Mannich reaction followed by substitution of 
the resulting Mannich base hydrochloride 1 with 
imidazole to furnish the pivotal ketone 2. 
Subsequently, the ketone function in compound 
2 was transformed to an oxime via reaction with 
hydroxylamine hydrochloride in the presence of 
potassium hydroxide to yield the oxime 3. 
Esterification of the hydroxyl moiety in compound 
3 with 3,4,5-trimethoxybenzoic acid in the 
presence of the coupling agent EDCI.HCl and 




1H-NMR (CDCl3): δ 3.44 (t, J = 6.5 Hz, 2H, -CH2-
CH2-N), 4.43 (t, J = 6.5 Hz, 2H, -CH2-CH2-N), 
6.98 (s, 1H, -N-CH=CH-N=), 7.03 (s, 1H, -N-
CH=CH-N=), 7.45–7.49 (m, 2H, Ar-H), 7.56-7.61 
(m, 2H, Ar-H, -N-CH=N-), 7.92 (d, J = 7.5 Hz, 2H, 
Ar-H); 13C-NMR (CDCl3): δ 39.9 (-CH2-CH2-N), 
41.5 (-CH2-CH2-N), 119.1 (-N-CH=CH-N=), 
127.9, 128.8, 129.6 (-N-CH=CH-N=, Ar-CH), 






1H-NMR (CDCl3): δ 3.31 (t, J = 7.1 Hz, 2H, -CH2-
CH2-N), 4.28 (t, J = 7.1 Hz, 2H, -CH2-CH2-N), 
6.96 (s, 1H, -N-CH=CH-N=), 7.07 (s, 1H, -N-
CH=CH-N=), 7.29–7.49 (m, 5H, Ar-H), 7.58 (s, 
1H, -N-CH=N-); 13C-NMR (CDCl3): δ 28.3 (-CH2-
CH2-N), 41.8 (-CH2-CH2-N), 119.1 (-N-CH=CH-
N=), 126.1, 128.8, 128.9 (-N-CH=CH-N=, Ar-
CH), 135.1, 137.0 (Ar-C), 139.5 (-N-CH=N-), 







1H-NMR (CDCl3): δ (ppm) = 3.45 (t, J = 6.8 Hz, 
2H, -CH2-CH2-N), 3.92 (s, 6H, 2 × OCH3), 3.94 (s, 
3H, OCH3), 4.28 (t, J = 6.8 Hz, 2H, -CH2-CH2-N), 
6.91 (s, 1H, -N-CH=CH-N=), 7.02 (s, 1H, -N-
CH=CH-N=), 7.27–7.50 (m, 6H, -N-CH=N-, Ar-H), 
7.67 (d, J = 7.0 Hz, 2H, Ar-H.); 13C-NMR (CDCl3): δ 
30.9 (-CH2-CH2-N), 43.6 (-CH2-CH2-N), 56.5 (2 × 
OCH3), 61.0 (OCH3), 106.9  (Ar-CH), 118.6 (-N-
CH=CH-N=), 123.5, 127.3, 129.1, 130.1, 131.3, 
132.9 (-N-CH=CH-N=, Ar-CH, Ar-C), 136.8 (-N-
CH=N-), 142.9, 153.2 (Ar-C), 163.2 (C=N), 163.6 
(C=O); MS m/z (ESI): 410.1 [M + 1]+ [8]. 
 
Crystal structure of the target oximino ester 4 
 
Cell refinement and data reduction were 
performed using Bruker SAINT [9]. SHELXS-97 
[10] was used to solve and refine the structure. 



























Scheme 1: Synthesis of the title compound 4. Reagents and conditions: i) HN(CH3)2.HCl, (CH2O)n, conc. HCl, 
ethanol, reflux, 2 h; ii) Imidazole, water, reflux, 5 h; iii) H2NOH.HCl, KOH, ethanol, reflux, 18 h; iv) 3,4,5-
Trimethoxybenzoic acid, EDCI.HCl, DMAP, DCM, rt, 18 h. 
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full-matrix least-squares techniques with 
anisotropic thermal data for non-hydrogen atoms 
on F2. All hydrogen atoms were placed in 
calculated positions and constrained to ride on 
their parent atoms. Multi-scan absorption 
correction was applied using SADABS software 
[9]. The crystallographic data and refinement 
information are summarized in Table 1, and the 
selected bond lengths and angles are listed in 
Table 2. The labeled displacement ellipsoid plot 
is shown in Figure 1, in which the minor 
disordered component has been omitted for 
clarity. Figure 2 depicts the packing of the 
molecules in the crystal structure. 
 
Table 1: Crystallographic data and refinement information. 
 
Molecular formula C22H23N3O5 
Mr 409.43 
Crystal system, space group Triclinic, P  
Temperature (K) 296 
a, b, c (Å) 11.0719 (7), 14.6602 (9), 14.8530 (9) 
α, β, γ (°) 67.205 (4), 80.388 (5), 70.100 (5) 
V (Å3) 2088.2 (2) 
Z 4 
Radiation type Cu Kα 
µ (mm−1) 0.77 
Crystal size (mm) 0.32 × 0.23 × 0.05 
Data collection 
Diffractometer Bruker APEX-II CCD  
diffractometer 
Absorption correction Multi-scan  
SADABS Bruker 2014 
Tmin, Tmax 0.790, 0.962 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
25011, 6450, 2607  
Rint 0.105 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.065, 0.189, 0.83 
No. of reflections 6450 
No. of parameters 548 
No. of restraints 0 
H-atom treatment H atoms treated by a mixture of independent and 
constrained refinement 
Δρmax, Δρmin (e Å−3) 0.24, −0.27 
 
Table 2: Selected geometric parameters, bond length and bond angles (Å, °). 
 
Atom Bond length (Å) Atom Bond angles (°) 
O1A—C2A 1.358 (5) C2A—O1A—C8A 118.0 (4) 
O1A—C8A 1.411 (7) C3A—O2A—C9A 113.2 (3) 
O2A—C3A 1.383 (5) C4A—O3A—C10A 116.8 (3) 
O2A—C9A 1.430 (6) N1A—O5A—C7A 113.7 (3) 
O3A—C4A 1.359 (5) C2B—O1B—C8B 117.6 (4) 
O3A—C10A 1.413 (5) C3B—O2B—C9B 113.3 (4) 
O4A—C7A 1.193 (5) C4B—O3B—C10B 118.1 (4) 
O5A—N1A 1.434 (4) N1B—O5B—C7B 114.5 (3) 
O5A—C7A 1.358 (5) O5A—N1A—C11A 109.2 (3) 
O1B—C2B 1.371 (6) C19A—N2A—C20A 127.5 (4) 
O1B—C8B 1.433 (7) C19A—N2A—C22A 126.6 (4) 
O2B—C3B 1.383 (5) C20A—N2A—C22A 105.7 (5) 
O2B—C9B 1.429 (7) C21A—N3A—C22A 109.9 (5) 
N1B—C11B 1.274 (5) C20B—N2B—C22B 106.6 (4) 
N2B—C19B 1.455 (6) C21B—N3B—C22B 110.1 (4) 
N2B—C20B 1.344 (6) O1A—C2A—C3A 115.7 (4) 
N2B—C22B 1.378 (6) O1A—C2A—C1A 124.5 (4) 
N3B—C22B 1.391 (7) O2A—C3A—C4A 120.1 (4) 
N3B—C21B 1.361 (7) O2A—C3A—C2A 118.6 (4) 
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The chemical structures of the synthesized 
compounds were confirmed via spectral analysis 
including 1H NMR, 13C NMR, and mass spectral 
data. The target oximino ester 4 has exhibited 
potential in vitro anti-Candida activity and has 
been evaluated using clinical isolates of C. 
albicans and C. tropicalis. It has a MIC value of 
0.3053 µmol/mL against both C. albicans and C. 
tropicalis and is approximately 5-fold more potent 
than the gold standard antifungal agent 
fluconazole (MIC ˃1.6325 µmol/mL) [8]. 
 
The configuration of the anti-Candida oximino 
ester 4 was confirmed via x-ray crystallography 
approach as an analytical tool to unequivocally 
assign its structure. In this manner, the imine 
group in the target compound 4 was assigned an 
(E)-configuration.  
 
The crystal structure of 4 contains two molecules 
in the asymmetric unit. The phenyl ring (C1-C6) 
forms dihedral angles of 8.76 (3)° and 12.13 (2)° 
with the benzene ring (C12-C17), in the two 
molecules. The phenyl ring (C1-C6) also forms 
dihedral angles of 70.75(1)° and 65.80(2)° with 
the imidazole ring (N2-C20-C21-N3-C22), in the 
two molecules. Furthermore, the phenyl ring 
(C12-C17) forms dihedral angles of 64.63 (1)° 
and 64.76(2)° with the imidazole ring (N2-C20-
C21-N3-C22) in the two molecules. The crystal 
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structure is stabilized by four C-H…O non-
classical hydrogen bonds along the c axis, where 
the length between C9A—H9AA is 0.96 Å, 
C9B—H9BA is 0.96 Å, C18B—H18C is 0.97 Å, 
and C20B—H20B is 0.93 Å. The angles between 
C9A—H9AA•••O3A(i), C9B—H9BA•••O3B(ii), 
C18B—H18C•••O2A(i), and C20B—H20B••• 
O4B(iii) are 169.00°, 162.00°, 165.00°, and 
163.00°, respectively, with the following 
respective symmetry codes: (i) −x, −y+2, −z; (ii) 




An x-ray single crystal molecular structure of the 
anti-Candida agent, namely (({[(1E)-3-(1H-
imidazol-1-yl)-1-phenylpropylidene]amino}oxy) 
(3,4,5-trimethoxyphenyl)methanone (4), has 
been obtained in this study. The assigned (E)-
configuration of the imine moiety in the target 
oximino ester 4 was confirmed via single-crystal 
x-ray crystallography as a decisive analytical 
tool. Compound 4 may be a promising new anti-
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